Sanofi Pasteur Selects Freeslate to Improve Formulation Development - - BioPharm International

ADVERTISEMENT

Sanofi Pasteur Selects Freeslate to Improve Formulation Development



Freeslate, a provider of high-throughput research solutions, reports that Sanofi Pasteur, the vaccines division of Sanofi, has purchased Freeslate’s Biologics Formulation System, which is usual in vaccine and protein formulation development. The system automates sample preparation, sample stressing, and formulation analysis, to allow for the development of stable, robust formulations more quickly with reduced API consumption.

Based on the Freeslate Core Module 3 automation platform, the Biologics Formulation System combines liquid dispense and controlled heating/cooling/mixing with new automated measurements of pH, viscosity, and particle counting. Integrated by Freeslate’s Lab Execution and Analysis software suite, the system allows for the control and data integration of a range of third-party analytics, including Dynamic Light Scatter, UV/VIS plate readers, and high pressure liquid chromatography.

Source: Freeslate

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Lilly to Acquire Novartis Animal Health
April 22, 2014
Novartis and GSK Trade Assets
April 22, 2014
Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
EMA Warns of Falsified Herceptin Vials
April 16, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Author Guidelines

Click here